InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
0
T+90 胜率
100%
T+90 平均收益
+9.6%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the full record of transactions filed by Saad Mark E, 董事. Officer active across 1 company, notably Axsome Therapeutics, Inc.. Aggregated, 5 reports have been logged. Breakdown: 1 buy · 0 sell. Total volume traded: €92k. History available since 17 November 2021. The latest transaction was disclosed on 31 December 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Saad Mark E
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
1,429 股Common StockSEC:0001193125-26-266436:0
6,231 股@ US$8.0217.6% 占其流量Common StockSEC:0001193125-26-001181:0
9,127 股@ US$9.0035.5% 占其流量Common StockSEC:0000950170-25-113311:0
11,016 股@ US$3.6716.7% 占其流量Common StockSEC:0000950170-24-105616:0
3,000 股@ US$34.532437.9% 占其流量Common StockSEC:0001209191-21-065696:0
标准退出：2022年2月15日 (T+90)
5 条申报中的 5 条
About Saad Mark E
Saad Mark E is a Board Member of Axsome Therapeutics, Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and oversight of operations. His experience in the pharmaceutical sector is an asset for Axsome Therapeutics, which focuses on developing innovative treatments.
